Eyetech Pharmaceuticals

CompanyUnited States

Eyetech Pharmaceuticals develops one asset, in phase 3, no development reported (pegaptanib sodium in age-related macular degeneration). Mostly oligonucleotide acting on VEGFA; based in the United States.

1
Asset
Furthest stage
Phase 3, no development reported
1
Trial
1
Signal

Pipeline

1
  • pegaptanib sodium

    RNA aptamer antagonist that selectively binds and inhibits vascular endothelial growth factor 165 (VEGF165).

    Phase 3, no development reported, Oligonucleotide, VEGFA, age-related macular degeneration

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Signals1
  • Similar companies6

Intelligence